
Nekkar - Q2 Review – Postponed Recovery

Redeye return with an updated view following Nekkar's Q2 figures that posted mixed figures during a slower period, where margins suffered from a temporary downturn. We lower our expectations on H2'25, now expecting a comeback in 2026 at first. The underlying fundamentals continue to develop well, supporting our positive long-term view.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Nekkar - Q2 Review – Postponed Recovery